tiprankstipranks

Jason Rhodes Insider Profile

4 Followers
Jason Rhodes, President, CFO and Treasurer at Epizyme, holds 9.13M shares in Dyne Therapeutics (Ticker: DYN), holds 8.28M shares in Generation Bio (Ticker: GBIO), holds 3.23M shares in Replimune Group (Ticker: REPL).
tipranks
Jason Rhodes

Jason Rhodes
Epizyme (EPZM)
President, CFO and Treasurer

Ranked #7,962 out of 100,516 Corporate Insiders

Profitable Transactions

50%
2 out of 4 Profitable Transactions

Average Return

+70.90%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$178M
71.82%
25.34%
2.84%
0.00%
A breakdown of Jason Rhodes's holdings

Insider Roles

Dyne Therapeutics
(DYN)
Director
Replimune Group
(REPL)
Director
Generation Bio
(GBIO)
Director
Disc Medicine
(IRON)
Director, Ten Percent Owner
Roles that Jason Rhodes holds in companies

Most Profitable Insider Trade

Stock:
Replimune Group
(REPL)
Rating:Informative Buy
Date:Nov 20, 2019 - Nov 20, 2020
Return:+276.70%
The most profitable trade made by Jason Rhodes

Jason Rhodes's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
EPZM
Epizyme
Sep 24, 2014
Informative Buy
22.44K
$202.86K
Replimune Group
Jan 28, 2021
Director
Uninformative Sell
256.45K
$45.14M
Generation Bio
Sep 29, 2021
Director
Uninformative Sell
2.06M
$5.05M
Dyne Therapeutics
Jan 29, 2025
Director
Uninformative Buy
15.00M
$127.92M
Disc Medicine
Director, Ten Percent Owner
List of latest transactions for each holding click on a transaction to see Jason Rhodes's performance on stock

Jason Rhodes insider profile FAQ

What is the percentage of profitable transactions made by Jason Rhodes?
The percentage of profitable transactions made by Jason Rhodes is 50%.
    What is the average return per transaction made by Jason Rhodes?
    The average return per transaction made by Jason Rhodes is 70.90%.
      What stocks does Jason Rhodes hold?
      Jason Rhodes holds: EPZM, REPL, GBIO, DYN, IRON stocks.
        What was Jason Rhodes’s latest transaction?
        Jason Rhodes latest transaction was an Uninformative Buy of $15.00M.
          What was Jason Rhodes's most profitable transaction?
          Jason Rhodes’s most profitable transaction was an Informative Buy of REPL stock on November 20, 2019. The return on the trade was 276.70%.
            What is Jason Rhodes's role in Epizyme?
            Jason Rhodes's role in Epizyme is President, CFO and Treasurer.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.